Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1959-1964, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stein, W.
Right arrow Articles by Maulbetsch, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stein, W.
Right arrow Articles by Maulbetsch, R.

Clinical Chemistry, Vol 31, 1959-1964, Copyright © 1985 by American Association for Clinical Chemistry

Macro creatine kinase type 2: results of a prospective study in hospitalized patients

W Stein, J Bohner, W Renn and R Maulbetsch

We determined total CK activity with the N-acetylcysteine-activated method and residual activity after immunoinhibition of the CK-M subunits in the sera of 2018 patients consecutively admitted to our university hospital for internal diseases, and of 936 outpatients, regardless of the patients' diagnoses. We could detect not more than two types of macro CK: macro CK type 2, which we observed in the sera of 85 patients (prevalence, 3.7% for hospitalized patients), and macro CK type 1. Most patients showing macro CK type 2 were older than 50 years, but we additionally observed a second peak at 20-30 years of age. We saw no preponderance by sex. We detected macro CK type 2 predominantly in severely ill patients of all ages, mainly those with malignant tumors or cirrhosis of the liver. Our findings support the assumption that macro CK type 2 is the manifestation of mitochondrial CK in serum. Occasionally, macro CK type 2 disappeared from the circulation after amelioration of the associated disease. Its occurrence in serum nevertheless is a sign of a serious illness with high mortality but not inevitably a sign of impending death.


The following articles in journals at HighWire Press have cited this article:


Home page
 Br Med BullHome page
P. Brancaccio, N. Maffulli, and F. M. Limongelli
Creatine kinase monitoring in sport medicine
Br. Med. Bull., June 14, 2007; (2007) ldm014v1.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
B. Galarraga, D. Sinclair, M. N. Fahie-Wilson, F. C. McCrae, R. G. Hull, and J. M. Ledingham
A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review
Rheumatology, January 1, 2003; 42(1): 186 - 188.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
F. F. Immer, F. P. Stocker, A. M. Seiler, J.-P. Pfammatter, G. Printzen, and T. P. Carrel
Comparison of troponin-I and troponin-T after pediatric cardiovascular operation
Ann. Thorac. Surg., December 1, 1998; 66(6): 2073 - 2077.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.